The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ostroumova O.D.

Kafedra fakul'tetskoĭ terapii i professional'nykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta im. A.I. Evdokimova, Moskva

Goloborodova I.V.

Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Isaev R.I.

Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Pereverzev A.P.

Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Antipsychotics: features of undesirable adverse reactions in elderly and senile age

Authors:

Ostroumova O.D., Goloborodova I.V., Isaev R.I., Pereverzev A.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2): 105‑117

DOI: 10.17116/jnevro2019119021105

Views: 22806

Downloaded: 387

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Ostroumova OD, Goloborodova IV, Isaev RI, Pereverzev AP. Antipsychotics: features of undesirable adverse reactions in elderly and senile age. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2):105‑117. (In Russ.)
https://doi.org/10.17116/jnevro2019119021105

 
МСФ на ЯМ
Close metadata
Recommended articles:
Cere­brolysin as an early add-on to repe­rfusion therapy: hete­rogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemo­rrhagic transformation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):55-66
Cognitive impairment in cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16
Algo­rithms for the diagnosis and treatment of cognitive impairment and dysphagia in stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):100-107
Brain-derived neurotrophic factor in the acute and early reco­very period of ischemic stroke: the role of nocturnal hypo­xemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):72-78
Pharmacotherapy of schi­zophrenia: clinical and some age-related aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):41-50
Comparison of the effe­ctiveness of non-immunogenic staphylokinase and alte­plase for intravenous thro­mbolysis in ischemic stroke: analysis of hospital regi­stry data. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):139-144
Arti­ficial ventilation in patients with stroke: main resu­lts of the Russian multicenter obse­rvational clinical trial RETAS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):5-13
The impact of the impairment of social cognitive functions in acute stage of stroke on its functional outcomes. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):21-25
Possibilities of mirror therapy in cognitive reha­bilitation after stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):64-71
Orga­nization of a Seco­ndary Fracture Prevention System. Expert group reco­mmendations. Russian Journal of Preventive Medi­cine. 2024;(8):26-31

This review summarizes and systematizes currently available literature on antipsychotics as one of the most frequently prescribed group of psychotropic drugs. Based on published data from clinical studies and meta-analyzes, the authors consider unwanted adverse reactions in patients taking antipsychotic medications. Mechanisms of development of undesirable drug reactions are discussed. Special attention is paid to those adverse reactions of antipsychotics that most often occur in old and very old age (increased risk of adverse cardiovascular and cerebrovascular events, sudden death, prolonged QTc interval, falls, fractures, orthostatic hypotension, extrapyramidal disorders, pneumonia, urinary tract infections, etc.).

Keywords:

antipsychotics; elderly and senile age; undesirable adverse reactions; cardiovascular events; stroke; falls
fractures

Authors:

Ostroumova O.D.

Kafedra fakul'tetskoĭ terapii i professional'nykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta im. A.I. Evdokimova, Moskva

Goloborodova I.V.

Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Isaev R.I.

Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Pereverzev A.P.

Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

List of references:

  1. Mosolov SN, Ryvkin PV, Serditov OV, Ladyzhenskii MYa, Potapov AV. Metabolicheskie narusheniya pri lechenii bol’nykh shizofreniei. RMZh. 2008;15:1028-1039. (In Russ.)
  2. Medvedev VE. Psikhosomaticheskie zabolevaniya: kontseptsiya i sostoyanie problemy. Arkhiv Vnutrennei Meditsiny. 2013;6(14):37-40. (In Russ.)
  3. Dorsey ER, Rabanni A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96-103. https://doi.org/10.1001/archinternmed.2009.456
  4. Psikhiatriya. Natsional’noe rukovodstvo. Pod red. Aleksandrovskogo YuA, Neznanova NG. M.: GEOTAR-Media; 2008. (In Russ.)
  5. Yastrebov DV. Antipsikhoticheskaya terapiya s ispol’zovaniem atipichnykh neiroleptikov. Ros Psikhiatr Zhurn. 2013;1:71-82. (In Russ.)
  6. Ballard C, Bannister C, Graham C, Oyebode F, Wilcock G. Associations of psychotic symptoms in dementia sufferers. British Journal of Psychiatry. 1995;167:537-540. https://doi.org/10.1192/bjp.167.4.537
  7. Bouman WP, Pinner G. Use of atypical antipsychotic drugs in old age psychiatry. Advances In Psychiatric Treatment. 2002;8:49-58. https://doi.org/10.1192/apt.8.1.49
  8. Briesacher BA, Limcangco MR, Simoni-Wastila L, Doshi JA, Levens SR, Shea DG, Stuart B. The Quality of Antipsychotic Drug Prescribing in Nursing Homes. Arch Intern Med. 2005;165(11):1280-1285. https://doi.org/10.1001/archinte.165.11.1280
  9. Golenkov AV. Narusheniya sna pri psikhicheskikh rasstroistvakh. Effektivnaya Farmakoterapiya. 2014;22:24-28. (In Russ.)
  10. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544. https://doi.org/10.1001/archpsyc.1992.01820070032005
  11. Ryzhenko IM. Pobochnye effekty, svyazannye sosobennostyami primeneniya antipsikhoticheskikh sredstv. Provizor. 2003;15. (In Russ.)
  12. Arana D, Rozenbaum D. Farmakoterapiya psikhicheskikh rasstroistv. M.: Binom; 2004. (In Russ.)
  13. Reist C, Mintz J, Albers LJ, Jamal MM, Szabo S, Ozdemir V. Second-Generation Antipsychotic Exposure and Metabolic-Related Disorders in Patients With Schizophrenia. Journal of Clinical Psychopharmacology. 2007;27(1):46-51. https://doi.org/10.1097/jcp.0b013e31802e5126
  14. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-184. https://doi.org/10.1002/pds.2082
  15. Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiology and Drug Safety. 2007;16:882-890.
  16. Baza dannyh NPR VOZ VigiBase. Ssylka aktivna na 18.12.18. (In Russ.) Availableat: http://www.vigiaccess.org
  17. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525-1538. https://doi.org/10.1056/NEJMoa061240
  18. Maglione M, Ruelaz Maher A, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-10062-1.) Rockville, MD, Agency for Healthcare Research and Quality, 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm
  19. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, Gurwitz JH, Rochon PA. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786. https://doi.org/10.7326/0003-4819-146-11-200706050-00006
  20. Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, Devanand DP, Lucas JA, Huang C, Malka ES, Levin R, Crystal S. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry. 2014;205(1):44-51. https://doi.org/10.1192/bjp.bp.112.122499
  21. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart A, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2014;183(7):411-419. https://doi.org/10.1503/cmaj.101406
  22. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:977. https://doi.org/10.1136/bmj.e977
  23. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235. https://doi.org/10.1056/nejmoa0806994
  24. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71-79. https://doi.org/10.1176/appi.ajp.2011.11030347
  25. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72:438-445. https://doi.org/10.1001/jamapsychiatry.2014.3018
  26. Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, Saxton J, McDade E, Kamboh MI, DeKosky ST, Reynolds CF, Klunk WE. The long-term effects of conventional and atypical ntipsychotics in patients with probable Alzheimer’s disease. Am J Psychiatry. 2013;170(9):1051-1058. https://doi.org/10.1176/appi.ajp.2013.12081046
  27. Rafaniello C, Lombardo F, Ferrajolo C, Sportiello L, Parretta E, Formica R, Potenza S, Rinaldi B, Irpino A, Raschetti R, Vanacore N, Rossi F, Capuano A. Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy. Eur J Clin Pharmacol. 2014;70(2):187-195. https://doi.org/10.1007/s00228-013-1588-3
  28. Buckley N, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety. 2000;23(3):215-228. https://doi.org/10.2165/00002018-200023030-00004
  29. Burke AD, Tariot PN. Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes. Expert Opin Pharmacother. 2009;10(15):2407-2414. https://doi.org/10.1517/14656560903200659
  30. Chatterjee S, Chen H, Johnson ML, Aparasu RR. Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity scoreadjusted retrospective cohort study. Drugs Aging. 2012;29(10):807-817. https://doi.org/10.1007/s40266-012-0013-4
  31. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, Normand S-LT, Gurwitz JH, Marras C, Wodchis WP, Mamdani M. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):44-52. https://doi.org/10.1136/bmj.38330.470486.8f
  32. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161(6):1113-1115. https://doi.org/10.2165/00023210-200519020-00001
  33. Liu ME, Tsai SJ, Chang WC, Hsu C-H, Lu T, Hung K-S, Chiu W-T, Chang W-P. Population-based 5-year follow-up study in Taiwan of dementia and risk of stroke. 2013;8(4):761-771. https://doi.org/10.1371/journal.pone.0061771
  34. Sacchetti E, Turrina C, Cesana B, Mazzaglia G. Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. J Psychopharmacol. 2009;24(7):1131-1132. https://doi.org/10.1177/0269881109103202
  35. Kleijer BC, van Marum RJ, Egberts AC, Jansen PAF, Knol W, Heerdink ER. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009;23(8):909-914. https://doi.org/10.1177/0269881108093583
  36. Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Risk of incident stroke in patients with Alzheimer disease or vascular dementia. Neurology. 2013;81(10):910-919. https://doi.org/10.1212/WNL.0b013e3182a35151
  37. Volkov VP. Kardiotoksichnost’ fenotiazinovykh neiroleptikov (obzor literatury). Psikhiatr. Psikhofarmakoterapiya. 2010;2:41-45. (In Russ.)
  38. Drobizhev MYu. Kardiologicheskie aspekty problemy perenosimosti i bezopasnosti neiroleptika. Psikhiatr. Psikhofarmakoter. 2004;2:60-68. (In Russ.)
  39. Montout C, Casadebaig F, Lagnaoui R, Verdoux H, Philippe A, Begaud B, Moore N. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res. 2002;57:147-156. https://doi.org/10.1016/s0920-9964(01)00325-5
  40. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller H-J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and European Society of Cardiology (ESC). Eur Psychiatry. 2009;6(24):412-424. https://doi.org/10.1016/j.eurpsy.2009.01.005
  41. Lawrence D, Kisely S, Pais J. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry. 2010;12(55):752-759. https://doi.org/10.1177/070674371005501202
  42. Mortensen PB, Juel K. Mortality and causes of death in schizophrenia in Denmark. Acta Psychiatr Scand. 1990;4(8):372-327. https://doi.org/10.1111/j.1600-0447.1990.tb05466.x
  43. Setoguchi S, Wang PS, Brookhart MA, Canning CF, Kaci L, Sebastian Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc. 2008;56(9):1644-1650. https://doi.org/10.1111/j.1532-5415.2008.01839.x
  44. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632. https://doi.org/10.1503/cmaj.070582
  45. Hartigan-Go K, Bateman D, Nyberg G, Martensson E, Thomas SHL. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60(5):543-553. https://doi.org/10.1016/s0009-9236(96)90150-2
  46. Gelly F, Chambon O, Marie-Cardine M. Long-term clinical experience with clozapine. Encephale. 1997;23(5):385-396.
  47. Pariente A, Fourrier-Reglat A, Ducruet T, Farrington P, Béland S-G, Dartigues J-F, Moore N, Moride Y. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172(8):648-653. https://doi.org/10.1001/archinternmed.2012.28
  48. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048-1052. https://doi.org/10.1016/S0140-6736(00)02035-3
  49. Physicians Desk Reference 56th edition. Medical Economics Company Inc, Montvale, NJ; 2002.
  50. Pfizer: Briefing document for ziprasidone HC1 presented at the FDA Psychopharmacological Drugs Advisory Committee; 2000.
  51. Green B. Focus on olanzapine. Curr Med Res Opin. 1999;15(2):79-85. https://doi.org/10.1185/03007999909113367
  52. Polcwiartek C, Sneider B, Graff C, Taylor D, Meyer J, Kanters JK, Nielsen J. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology. 2015;232(18):3297-3308. https://doi.org/10.1007/s00213-015-4024-9
  53. Hunt N, Stern T. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. Psychosomatics. 1995;36(6):541-549. https://doi.org/10.1016/s0033-3182(95)71609-7
  54. Sharma N, Rosman H, Padhi I, Tisdale J. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998;81(2):238-240. https://doi.org/10.1016/s0002-9149(97)00888-6
  55. Di Salvo T, O’Gara P. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol. 1995;18(5):285-290. https://doi.org/10.1002/clc.4960180512
  56. O’Brien J, Rockwood R, Suh K. Haloperidol-induced torsade de pointes. Ann Pharmacother. 1999;33(10):1046-1050. https://doi.org/10.1345/aph.19017
  57. Volkov VP. Vnezapnaya smert’ bol’nykh shizofreniei. Verkhnevolzhsk Med Zhurn. 2009;7(2):3-7. (In Russ.)
  58. DA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients (FDA talk Paper). Rochvill (MD): US Food and Drug Adminstration; 2006.
  59. Herxheimer A, Healy D. Arrythmias and sudden death in patients taking antipsychotic drugs. Br Med J. 2002;325:1253-1254. https://doi.org/10.1136/bmj.325.7375.1253
  60. Mazur NA. Vnezapnaya smert’ bol’nykh ishemicheskoi bolezn’yu serdtsa. M.: Meditsina; 1985. (In Russ.)
  61. Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry. 1990;51(11):459-462. PMID: 1977739.
  62. Akın S, Bahat G, Tufan F, Saka B, Oztop N, Erten N, Karan MA. Olanzapine as a cause of peripheric edema in an elderly man. Aging Clinical and Experimental Research. 2013;25(1):115-117. https://doi.org/10.1007/s40520-013-0002-4
  63. Hwang JP, Yang CH, Yu HC, Chang J-W, Cheng C-Y, Tsai S-J. The efficacy and safety of risperidone for the treatment of geriatric psychosis. J Clin Psychopharmacol. 2001;21(6):583-587. https://doi.org/10.1177/0269881105056669
  64. Durst R, Raskin S, Katz G, Zislin J, Durst R. Pedal edema associated with clozapine use. IMAJ. 2000;2:485-486. PMID: 10897248.
  65. Ng B, Postlethwaite A, Rollnik J. Peripheral oedema in patients taking olanzapine. Int Clin Psychopharmacol. 2003;18:57-59. https://doi.org/10.1097/00004850-200301000-00010
  66. Rozzini L, Ghianda D, Vicini Chilovi B, Padovani A, Trabucchi M. Peripheral Oedema Related to Quetiapine Therapy. Drugs & Aging. 2005;22(2):183-184. https://doi.org/10.2165/00002512-200522020-00007
  67. Bouman WP, Pinner G. Use of atypical antipsychotic drugs in old age psychiatry. Advances in psychiatric treatment. 2002;8:49-58. https://doi.org/10.1192/apt.8.1.49
  68. Kolykhalov IV. Lechenie povedencheskikh i psikhoticheskikh simptomov dementsii vo vnebol’nichnykh usloviyakh. Metodicheskie rekomendatsii. M.: Nauchnyi tsentr psikhicheskogo zdorov’ya; 2012. (In Russ.)
  69. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995;52:756-765. https://doi.org/10.1001/archpsyc.1995.03950210050010
  70. Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndrome. American Journal of Geriatric Psychiatry. 2000;8:29-34. https://doi.org/10.1097/00019442-200002000-00004
  71. Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shulman KI, Stukel T, Normand S-L, Rochon PA. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc. 2005;53:1374-1379. https://doi.org/10.1111/j.1532-5415.2005.53418.x
  72. Vasilyeva I, Biscontri RG, Enns MW, Metge CJ, Alessi-Severini S. Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study. PLoS ONE. 2013;8(5): 64217. https://doi.org/10.1371/journal.pone.0064217
  73. Mosolov SN. Sovremennaya antipsikhoticheskaya framakoterapiya shizofrenii. RMZh. 2004;10:646-652. (In Russ.)
  74. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316(7):363-369. https://doi.org/10.1056/NEJM198702123160702
  75. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):807-816. https://doi.org/10.1007/s00198-005-0065-y
  76. Pouwels S, van Staa TP, Egberts AC, Leufkens HGM, Cooper C, de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2009;20(9):1499-1506. https://doi.org/10.1007/s00198-008-0826-5
  77. Sorensen HJ, Jensen SO, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013;23(8):872-878. https://doi.org/10.1016/j.euroneuro.2013.04.002
  78. Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc. 2010;11(2):120-127. https://doi.org/10.1016/j.jamda.2009.10.001
  79. Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf. 2011;34(7):567-575. https://doi.org/10.2165/00128415-201113630-00003
  80. Wang M, Hou R, Jian J, Mi G, Qiu H, Cao B, Tang M. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol. 2014;29(2):183-189. https://doi.org/10.1002/hup.2387
  81. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M, Correll CU, Kishimoto T. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res. 2013;147(2-3):383-386. https://doi.org/10.1016/j.schres.2013.04.015
  82. Okita K, Kanahara N, Nishimura M, Yoshida T, Yasui-Furukori N, Niitsu T, Yoshida T, Ishikawa M, Kimura H, Nomura F, Iyo M. Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res. 2014; 157(1-3):137-141. https://doi.org/10.1016/j.schres.2014.05.009
  83. Davis JM, Ramsden CE. Do antipsychotics cause hip fractures? Promise and pitfalls of big data. Journal of Clinical Psychiatry. 2015;76(9):1155-1156. https://doi.org/10.4088/JCP.14com09551
  84. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart A, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183(7):411-419. https://doi.org/10.1503/cmaj.101406
  85. Knol W, van Marum RJ, Jansen PAF, Souverein PC, Schobben AFAM, Egberts ACG. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):661-666. https://doi.org/10.1111/j.1532-5415.2007.01625.x
  86. Trifiro G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, Sturkenboom MC. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152(7):418-425. https://doi.org/10.7326/0003-4819-152-7-201004060-00006
  87. Herzig SJ, LaSalvia MT, Naidus E, Rothberg MB, Zhou W, Gurwitz JH, Marcantonio ER. Antipsychotics and the Risk of Aspiration Pneumonia in Individuals Hospitalized for Nonpsychiatric Conditions: A Cohort Study. J Am Geriatr Soc. 2017;12(65):2580-2586. https://doi.org/10.1111/jgs.15066
  88. Tan L, Tan L, Wang HF, Jun Wang J, Tan C-C, Tan M-S, Meng X-F, Wang C, Yu J-T. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis Alzheimer’s. Research & Therapy. 2015;7:20. https://doi.org/10.1186/s13195-015-0102-9

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.